Aduro Biotech
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Show More
CEO
Stephen Isaacs
Employees
105
Country
United States
ISIN
US00739L1017
WKN
000A2QE43
Listings
0 Comments
Share your thoughts
FAQs
What is Aduro Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Aduro Biotech stocks are traded under the ticker 290.STU.
How many employees does Aduro Biotech have?▼
As of November 2, 2026, the company has 105 employees.
In which sector is Aduro Biotech located?▼
Aduro Biotech operates in the Manufacturing sector.
When did Aduro Biotech complete a stock split?▼
The last stock split for Aduro Biotech was on October 2, 2020 with a ratio of 1:5.
Where is Aduro Biotech headquartered?▼
Aduro Biotech is headquartered in Berkeley, United States.